Visugromab in Cachexia International Trial
A phase 2/3 trial of Visugromab, run by CatalYm GmbH, now recruiting.
Overview
Visugromab in Cachexia International Trial is a phase 2/3 interventional study registered as NCT07112196 by CatalYm GmbH, with 518 participants planned, started 2026-04-16. Conditions listed: Cancer-associated Cachexia. No results are recorded here; the registry entry is the source.
Setting
Adaptive, Phase 2/3, Randomized, Double-Blind Trial Investigating the Efficacy and Safety of Visugromab Versus Placebo in Patients With Cancer-associated Cachexia
Phase
Phase 2/3
Sponsor
CatalYm GmbH
Registry
Enrolled
518
Similar pages
not linked directly; found by shared links- TrialTrial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC
Shares Visugromab, CatalYm.
- TrialVisugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)
Shares Visugromab, CatalYm.
- TrialTrial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC
Shares Visugromab, CatalYm.